TABLE 3.
Summary of forthcoming antiviral treatments in phase 3 trials
| Antiviral drug | Viral infection | % efficacya | Mechanism(s) of action | Study progressb |
|---|---|---|---|---|
| Sofosbuvir + velpatasvir | HCV genotypes 1–6 | 97.4 | Inhibit activities of HCV NS5B polymerase and NS5A, respectively | Phase 3, completed |
| Daclatasvir + asunaprevir | HCV genotype 1 | 86.4 | Daclatasvir, asunaprevir, and beclabuvir inhibit activities of NS5A, NS3/4A protease, and NS5B, respectively | Phase 4, ongoing |
| Daclatasvir + asunaprevir + beclabuvir | HCV genotype 1 | 91.5 | Phase 3, ongoing | |
| FV100 | VZV | 87.6 | Inhibits activity of the VZV DNA polymerasec | Phase 3, ongoing |
| Letermovir | HCMV | 71 | Targets the pUL56 subunit of the HCMV terminase complex to block viral DNA processing and/or packagingd | Phase 3, ongoing |
a
For HCV inhibitors, drug efficacy is measured by the SVR12 (see the text). For the VZV inhibitor FV100, drug efficacy is measured by the incidence of patients without postherpetic neuralgia after treatment at 90 days. For the HCMV inhibitor letermovir, drug efficacy is measured by the incidence of successful prophylaxis after treatment at 12 weeks (392).
b
Clinical data were extracted from ClinicalTrials.gov (see https://www.clinicaltrials.gov/) in April 2016.
c
See reference 385.